Therapy Detail

Therapy Name MRX34
Therapy Description

MRX34 is a liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity through inhibition of MYC, MET, BCL2, CCND1 and CTNNB1 (NCI Drug Dictionary; PMID: 24657911).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
MRX34 BCL2 inhibitor 15 c-MYC Inhibitor 9 MET Inhibitor 50 MRX34 is a liposomal formulation containing a nucleotide that mimics the human tumor suppressor microRNA (miRNA) miR-34, with potential antineoplastic activity through inhibition of MYC, MET, BCL2, CCND1 and CTNNB1 (NCI Drug Dictionary; PMID: 24657911).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown malignant glioma not applicable MRX34 Preclinical Actionable In a preclinical study, MRX34 (miR-34a) induced apoptosis and inhibited growth of glioma cells in culture and in xenograft models (PMID: 19773441). 19773441
Unknown unknown Advanced Solid Tumor not applicable MRX34 Phase I Actionable In a Phase I trial, MRX34 treatment in advanced solid tumor patients resulted in some preliminary efficacy, including a partial response lasting 48 weeks in one patient with hepatocellular carcinoma and four patients with stable disease (PMID: 27917453). 27917453 detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01829971 Phase I MRX34 A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection Terminated